Metenkefalin
drugOn this page
Also known as (met5)-enkephalinInno-105Met-enkephalinMetencefalinaMetenkefalineMethionine enkephalinNSC-374896Opioid growth factorSh-pentapeptide-19Tyr-gly-gly-phe-met
Summary
Metenkefalin (CHEMBL2108291) is a phase-3 clinical-stage unknown targeting OPRD1, OPRK1, and OPRM1; indicated across 6 conditions including relapsing-remitting multiple sclerosis and severe acute respiratory syndrome.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Targets: 3 (OPRD1, OPRK1, OPRM1)
- Indications: 6 conditions
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108291 |
| Name | Metenkefalin |
| Type | Unknown |
| Max phase | 3 |
Also known as: (met5)-enkephalin, Inno-105, Met-enkephalin, Metencefalina, Metenkefalin, Metenkefaline, Methionine enkephalin, NSC-374896, Opioid growth factor, Sh-pentapeptide-19, Tyr-gly-gly-phe-met, METENKEFALIN
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| OPRD1 | δ receptor | Full agonist | 7.4 | 0.2% | P41143 |
| OPRK1 | κ receptor | Full agonist | 6 | 0% | P41145 |
| OPRM1 | μ receptor | Full agonist | 9.2 | 0% | P35372 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 3 target gene(s): OPRD1, OPRK1, OPRM1.
Top Reactome pathways
6 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Peptide ligand-binding receptors | 3 | OPRD1, OPRK1, OPRM1 |
| G alpha (i) signalling events | 3 | OPRD1, OPRK1, OPRM1 |
| Interleukin-4 and Interleukin-13 signaling | 2 | OPRD1, OPRM1 |
| MECP2 regulates neuronal receptors and channels | 2 | OPRK1, OPRM1 |
| Opioid Signalling | 1 | OPRM1 |
| G-protein activation | 1 | OPRM1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| G protein-coupled receptor signaling pathway | 3 |
| adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | 3 |
| phospholipase C-activating G protein-coupled receptor signaling pathway | 3 |
| neuropeptide signaling pathway | 3 |
| G protein-coupled opioid receptor signaling pathway | 3 |
| signal transduction | 3 |
| immune response | 2 |
| G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | 2 |
| response to nicotine | 2 |
| eating behavior | 2 |
| response to ethanol | 2 |
| sensory perception | 2 |
| sensory perception of pain | 2 |
| adult locomotory behavior | 1 |
| negative regulation of gene expression | 1 |
Indications & clinical
Indications
6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| relapsing-remitting multiple sclerosis | 3 | MONDO:0005314 | EFO:0003929 |
| severe acute respiratory syndrome | 2 | MONDO:0005091 | MONDO:0100096 |
| exocrine pancreatic carcinoma | 2 | MONDO:0005192 | EFO:0002618 |
| squamous cell carcinoma | 2 | MONDO:0005096 | EFO:0000707 |
| hepatocellular carcinoma | 1 | MONDO:0007256 | EFO:0000182 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04374032 | PHASE2/PHASE3 | COMPLETED | Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection |
| NCT00109941 | PHASE2 | COMPLETED | Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery |
| NCT00982696 | PHASE2 | TERMINATED | Treatment of Advanced Head and Neck Cancer |
| NCT00255333 | PHASE1 | TERMINATED | INNO-105 in Patients With Solid Tumors |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
613 molecules share ≥1 primary target. Top 60 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| Dihydroergotamine | ChEMBL + PubChem | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| PROPOXYPHENE | ChEMBL + PubChem | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| TAFAMIDIS | ChEMBL + PubChem | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| ALVIMOPAN | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| AMIODARONE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| AMLODIPINE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| AMOXAPINE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| ASTEMIZOLE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| BENZTROPINE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| BUPRENORPHINE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| BUTORPHANOL | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| CANDESARTAN CILEXETIL | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| CANNABIDIOL | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| CHLORPROMAZINE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| CINNARIZINE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| CLOTRIMAZOLE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| CODEINE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| DIETHYLSTILBESTROL | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| ECONAZOLE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| FENTANYL | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| FLUPHENAZINE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| FLUSPIRILENE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| HYDROCODONE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| HYDROMORPHONE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| LANSOPRAZOLE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| LEVORPHANOL | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| LOPERAMIDE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| LOXAPINE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| MEPERIDINE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| METHADONE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| METHYLNALTREXONE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| MICONAZOLE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| MORPHINE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| NAFTOPIDIL | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| NALBUPHINE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| NALFURAFINE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| NALMEFENE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| NALOXONE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| NALTREXONE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| NELFINAVIR | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| OLICERIDINE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| OXYCODONE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| OXYMORPHONE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| PAROXETINE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| PASIREOTIDE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| PENTAZOCINE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| PIMOZIDE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| RALOXIFENE | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| RITONAVIR | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| SAMIDORPHAN | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| SAQUINAVIR | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| SUNITINIB | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| TAMOXIFEN | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| TRAMADOL | ChEMBL | Phase 4 (approved) | OPRD1, OPRK1, OPRM1 |
| ASIMADOLINE | ChEMBL | Phase 3 | OPRD1, OPRK1, OPRM1 |
| ATICAPRANT | ChEMBL | Phase 3 | OPRD1, OPRK1, OPRM1 |
| CEBRANOPADOL | ChEMBL | Phase 3 | OPRD1, OPRK1, OPRM1 |
| NAVACAPRANT | ChEMBL | Phase 3 | OPRD1, OPRK1, OPRM1 |
| TRIMEBUTINE | ChEMBL | Phase 3 | OPRD1, OPRK1, OPRM1 |
| BREMAZOCINE | ChEMBL | Phase 2 | OPRD1, OPRK1, OPRM1 |
Related Atlas pages
- Genes: OPRD1, OPRK1, OPRM1
- Diseases: relapsing-remitting multiple sclerosis
- Drugs: Dihydroergotamine, Propoxyphene, Tafamidis, Alvimopan, Amiodarone, Amlodipine, Amoxapine, Astemizole, Benztropine, Buprenorphine, Butorphanol, Candesartan Cilexetil, Cannabidiol, Chlorpromazine, Cinnarizine, Clotrimazole, Codeine, Diethylstilbestrol, Econazole, Fentanyl, Fluphenazine, Fluspirilene, Hydrocodone, Hydromorphone, Lansoprazole, Levorphanol, Loperamide, Loxapine, Meperidine, Methadone, Methylnaltrexone, Miconazole, Morphine, Naftopidil, Nalbuphine, Nalfurafine, Nalmefene, Naloxone, Naltrexone, Nelfinavir, Oliceridine, Oxycodone, Oxymorphone, Paroxetine, Pasireotide, Pentazocine, Pimozide, Raloxifene, Ritonavir, Samidorphan, Saquinavir, Sunitinib, Tamoxifen, Tramadol, Asimadoline, Aticaprant, Cebranopadol, Navacaprant, Trimebutine